若生智能
Drug Database
AN

anakinra (PerkinRA)

✓ Approved

PersisGen Par · IL1R1 · 重组蛋白

什么是 anakinra？

anakinra 是一种重组蛋白，由PersisGen Par研发。该药已获批，用于治疗相关适应症，给药途径：Injectable (Others)、Intravenous (IV)、Subcutaneous Injection。

药物档案

商品名PerkinRA
公司PersisGen Par
药物类别重组蛋白
分子靶点IL1R1
给药途径Injectable (Others), Intravenous (IV), Subcutaneous Injection
状态Approved
来源： ClinicalTrials.gov, PersisGen Par

作用机制

分子靶点

anakinra 作用于 1 个分子靶点：

IL1R1interleukin 1 receptor type 1 (P80, CD121A)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

anakinra 针对 11 个适应症，涉及 5 个治疗领域。

治疗领域疾病/病症分期
Musculoskeletal and connective tissue disordersRheumatoid arthritis✓ Approved
Musculoskeletal and connective tissue disordersStill's disease✓ Approved
Musculoskeletal and connective tissue disordersJuvenile idiopathic arthritis✓ Approved
Congenital, familial and genetic disordersChronic infantile neurological cutaneous and articular syndrome✓ Approved
Congenital, familial and genetic disordersMuckle-Wells syndrome✓ Approved

注册免费账户还可查看另外 6 个适应症

免费注册查看全部适应症 →

相关研究文献

PubMedJACC. Case reports2026-08-07

Relapsing-Remitting Perimyocarditis and Emerging Acute Myeloid Leukemia.

Zipperer-Giblin Madeline B MB, Bowman John I JI, Patel Nidhi N, Rinde-Hoffman Debbie D

Perimyocarditis as an initial manifestation of acute myeloid leukemia (AML) is rare, with fewer than 5 contemporary cases reported. A 66-year-old man experienced 7 hospitalizations over 3 months for fever, elevated troponin, and inflammatory markers after Coxsackievirus B exposure. Initial cardiac magnetic resonance (CMR), infectious, and hematologic work-ups were unremarkable. Repeat CMR revealed biventricular dysfunction, new lateral wall late gadolinium enhancement, myocardial edema, and a circumferential pericardial effusion. Endomyocardial biopsy confirmed severe lymphocytic myocarditis. The patient failed 2 corticosteroid tapers but improved with colchicine, intravenous immunoglobulin, and anakinra. After cardiac recovery, peripheral blood and bone marrow evaluation revealed AML. This case highlights a potential rare dual-etiology mechanism for perimyocarditis involving viral injury and AML-driven inflammatory activation. This case underscores the diagnostic value of serial CMR with biopsy, the role of interleukin-1 blockade and intravenous immunoglobulin in steroid refractory disease, and vigilance for emerging hematologic malignancy.

PMID 42563615
阅读全文 →
PubMedRespiratory research2026-08-06

Utility of mouse precision cut lung slices as an in vitro model for interrogating the lung immune response against bacterial pathogens in the context of immunomodulatory therapeutics.

Liu Guanghui G, Busch Susann S, Cohen Taylor S TS, Särén Linnea L et al.

High rates of respiratory infections have been observed in patients following treatment with immunomodulatory therapeutics, yet preclinical assessment and mechanistic understanding of drug-associated infection risk remains a challenge. Here, an ex vivo infection model of mouse precision-cut lung slices (PCLS) is described to address this gap. Naïve mouse PCLS were pre-treated with immunomodulatory drugs previously reported to exacerbate clinical infection risk (Idelalisib, Anakinra and Tofacitinib), followed by incubation with the lung pathogen Streptococcus pneumoniae. Bacterial uptake by the PCLS and cytokine release was measured to assess innate responses. Both Anakinra and Tofacitinib increased intracellular accumulation of bacteria within epithelial cells and reduced inflammatory cytokine release in a dose-dependent manner. Idelalisib also increased bacterial uptake with an inverse dose-response relationship, while the inhibitory effects on cytokine release were dose-dependent. These effects were confirmed in normal human bronchial epithelial cells (NHBE), suggesting that low concentrations of Idelalisib might negatively impact essential innate immune pathways. RNA-Seq analysis of the lung slices revealed the activation of key pathways linked to the innate immune response following infection, including PI3K signaling, oxidative stress response, cytoskeletal reorganization and autophagy. Notably, these pathways were modulated in the presence of Idelalisib and translation of the involvement of these pathways in the response to S. pneumoniae was confirmed in NHBE. In conclusion, the PCLS model offers potential to inform early risk assessment whilst aiding mechanistic understanding of the immunomodulatory impact of drug candidates on the lung.

PMID 42557569
阅读全文 →
PubMedReumatologia clinica2026-08-04

Case report of CRIA syndrome: progression from initial response to anakinra to sustained control with tocilizumab.

Hernández Sánchez Judith J, García Olivas Doryan José DJ, Machín García Sergio S, Hernández Beriain José Ángel JÁ

We present the case of a 40-day-old female infant with acute febrile illness, cutaneous lesions, severe respiratory distress, and shock refractory to antibiotic therapy. Skin biopsy revealed findings consistent with acute febrile neutrophilic dermatosis (Sweet syndrome). After excluding infectious, hematological, and hemophagocytic etiologies, an autoinflammatory syndrome was suspected, and treatment with anakinra and glucocorticoids was initiated, resulting in initial clinical improvement. However, after one year of treatment and dose tapering, the patient experienced relapses. Tocilizumab was then started, leading to a sustained clinical response to date.

PMID 42547316
阅读全文 →
PubMedCureus2026-08-02

Effective Multi-agent Therapy With Anakinra, Corticosteroids and Mycophenolate in Immunotherapy-Associated Haemophagocytic Lymphohistiocytosis (HLH).

Tanmoy Anirban Deb AD, Eaw Fan Jiong FJ, Mykura Charlotte C, Pradeep Dhanush Sheeba DS et al.

Haemophagocytic lymphohistiocytosis (HLH) is a rare, life-threatening complication of immune checkpoint inhibitor (ICI) therapy. Clinical overlap with sepsis contributes to delayed diagnosis and high mortality, showing the need for prompt recognition and targeted immunosuppression. This case presents a successful treatment pathway for HLH with high-dose methylprednisolone, mycophenolate mofetil (MMF) and anakinra, as well as emphasising the importance of early detection and management of HLH. A man in his sixties with stage IV cutaneous melanoma presented six weeks after the first cycle of ipilimumab and nivolumab immunotherapy with persistent high-grade fever, rigours, myalgia, malaise, and weight loss. Initial investigations revealed no infectious source, but computed tomography (CT) scans showed splenomegaly, and laboratory findings, including high ferritin, hypertriglyceridemia, high aspartate aminotransferase (AST), and low cell counts in two lines (lymphopenia and thrombocytopenia), met the modified HLH-2009 diagnostic criteria within 72 hours. Absence of melanoma progression, infection, or genetic predisposition suggested immunotherapy as the trigger. Treatment commenced on day 1 with anakinra and high-dose intravenous methylprednisolone, with mycophenolate mofetil added on day 3 due to worsening transaminitis, indicative of concurrent immunotherapy-induced hepatitis. The patient became afebrile within 48 hours, with ferritin normalising by day 10 and haematological and biochemical markers returning to normal. Anakinra was discontinued after 14 days. Complications included steroid-induced hyperglycemia, herpes simplex infection, and insomnia, all managed medically. At one-month follow-up, the patient remained asymptomatic with no HLH recurrence during immunosuppression tapering. This case highlights that steroids remain the primary acute treatment for HLH and immune-mediated disorders, with anakinra effectively inhibiting Interleukin-1 driven cytokine overproduction and mycophenolate mofetil addressing immune-related hepatitis. The combination of anakinra, mycophenolate mofetil, and high-dose methylprednisolone achieved rapid clinical and biochemical remission within 10 days, consistent with adult HLH consensus guidelines advocating early, multi-agent immunosuppression to prevent relapse in hyperinflammatory syndromes. Close monitoring of HLH biomarkers and a low threshold for suspicion in febrile patients on immunotherapy is recommended to facilitate timely intervention.

PMID 42541214
阅读全文 →
PubMedCureus2026-08-02

Adult-Onset Still's Disease Presenting as Fever of Unknown Origin: A Case Report.

Macedo Diogo D, de Sousa Melo Ana Rita AR, Amaral Pinto Inês I, Cruz Isabel I

Adult-onset Still's disease (AOSD) is a rare systemic autoinflammatory disorder that should be considered in patients presenting with fever of unknown origin (FUO). Diagnosis is challenging due to overlapping features with infectious, autoimmune, and hematological conditions. We report the case of a 19-year-old female presenting with a six-day history of persistent fever, later developing an evanescent rash and migratory polyarthralgia. Laboratory findings included cytopenias, elevated inflammatory markers, and markedly elevated ferritin levels. After ruling out infectious, autoimmune, and neoplastic etiologies, AOSD was diagnosed based on the Yamaguchi classification criteria. Initial treatment with corticosteroids led to partial clinical improvement, but persistent articular symptoms required escalation to anakinra, resulting in complete remission. This case reinforces that AOSD should be considered in the differential diagnosis of FUO, particularly in the presence of quotidian fever, rash, polyarthralgia, and marked hyperferritinemia. Early recognition and appropriate treatment, including biological therapy, are essential to control disease activity and prevent complications.

PMID 42542898
阅读全文 →
PubMedCurrent opinion in immunology2026-08-01

Recurrent pericarditis in children: evidence, controversies, and emerging perspectives.

Mauro Angela A, Baldassarre Paola P, Zicoia Marianna M, Bizzi Emanuele E et al.

Recurrent pericarditis complicates approximately one-third of initial pericarditis episodes in children. Once considered a postinfectious sequel, it is now understood as an autoinflammatory disorder sustained by dysregulated interleukin-1 signaling and inflammasome hyperactivation. This review evaluates therapeutic strategies for idiopathic recurrent pericarditis in patients younger than 18 years using the PICO framework. First-line management with nonsteroidal anti-inflammatory drugs and colchicine remains the therapeutic backbone, with colchicine conferring a roughly 50% reduction in relapse risk. Glucocorticoids, although acutely effective, predispose to steroid-dependence and rebound flares, and should be reserved for refractory disease at low doses. IL-1 receptor antagonism, principally anakinra, has emerged as a transformative steroid-sparing option for colchicine-resistant or steroid-dependent cases, achieving rapid symptom control and durable remission in most treated children. Nonetheless, pediatric evidence remains limited to retrospective cohorts and small case series, highlighting the need for prospective controlled trials, standardized outcome definitions, and long-term safety surveillance of biologic agents.

PMID 42537624
阅读全文 →

注册免费账户还可查看另外 3165 篇文献

免费注册查看全部文献 →

了解更多anakinra